Advances in psychiatry and nuerology


ISSN 1234-8279

ISSN on-line 2449-9315 

 

As of July 2026, the journal's publisher is Wroclaw Medical University: https://ppn.umw.edu.pl/en/about/.

 

CiteScore 2025: 0.4

MNiSW: 20

Index Copernicus 2023: 90.54

Editorial panel
Submitting and reviewing works online
  • Home page
  • >
  • Archive
  • >
  • issue 1
  • >
  • Farmakologiczne i kliniczne własności wenlafaksyny, nowego leku przeciwdepresyjnego

Archive 1995–2023

2000, volume 16, issue 1
Article

Farmakologiczne i kliniczne własności wenlafaksyny, nowego leku przeciwdepresyjnego

Janusz Rybakowski1, Jan Jaracz1
1. Klinika Psychiatrii Dorosłych AM w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii, 2000, 1, 83-96
Summary

In this review paper, pharmacological and c1inical properties of venlafaxine, the first selective serotonin and noradrenaline reuptake inhibitor were presented. High c1inical efficacy of venlafaxine in the treatment of depression was proved in numerous studies using placebo and reference drugs. Venlafaxine is effective in broad spectrum of depressions inc1uding severe and drug resistant depression as well as in prophylaxis of depressive recurrences. Rapid increasing of venlafaxine dose accelerates the onset of c1inical response. Venlafaxine is well tolerated by depressive patients. The drug exerts limited effect on the enzymes of cytochrome P-450. The risk of interaction of venlafaxine with other drugs concerns mainly monoamine oxidase inhibitors.

You have added an item to your cart
Restore password
Shopping cart (0)
No products in your cart
Font size
Contrast
Underlined links